Ono Pharmaceutical Retained Earnings (Accumulated Deficit) 2010-2024 | OPHLF

Ono Pharmaceutical retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Ono Pharmaceutical Retained Earnings (Accumulated Deficit) 2010-2024 | OPHLF

Ono Pharmaceutical retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$76.8B
Chugai Pharmaceutical (CHGCY)$66.9B
Takeda Pharmaceutical (TAK)$42.4B
Sandoz Group AG (SDZNY)$20.6B
Merck (MKKGY)$20B
Astellas Pharma (ALPMY)$17.7B
United Therapeutics (UTHR)$16.6B
Summit Therapeutics (SMMT)$16B
Neurocrine Biosciences (NBIX)$15.3B
Shionogi (SGIOY)$12.5B
Orion OYJ (ORINY)$7.5B
Madrigal Pharmaceuticals (MDGL)$7.1B
Stevanato Group S.p.A (STVN)$6.5B
Corcept Therapeutics (CORT)$6.4B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ionis Pharmaceuticals (IONS)$5.2B
Grifols, S.A (GRFS)$4.8B
Crinetics Pharmaceuticals (CRNX)$3.7B
Catalyst Pharmaceuticals (CPRX)$2.9B
Recursion Pharmaceuticals (RXRX)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Centessa Pharmaceuticals (CNTA)$2.2B
Soleno Therapeutics (SLNO)$2.1B
Hypermarcas (HYPMY)$1.9B
NewAmsterdam Pharma (NAMS)$1.9B
Indivior (INDV)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.7B
Evotec AG (EVO)$1.5B
Guardian Pharmacy Services (GRDN)$1.4B
ARS Pharmaceuticals (SPRY)$1.4B